StreetInsider.com News Articles

Form SCHEDULE 13G/A LENZ Therapeutics, Inc. Filed by: Ridgeback Capital Investments L.P.

Tue, 17 Feb 2026 16:03:00 -0500

si-local-file:///var/storage/secattach/20260217/26012233.html

Form SCHEDULE 13G/A LENZ Therapeutics, Inc. Filed by: Ridgeback Capital Investments L.P.

Tue, 17 Feb 2026 16:03:00 -0500

si-local-file:///var/storage/secattach/20260217/26012233.html

Form SCHEDULE 13G/A LENZ Therapeutics, Inc. Filed by: FMR LLC

Thu, 05 Feb 2026 13:28:00 -0500

si-local-file:///var/storage/secattach/20260205/25953620.html

Form SCHEDULE 13G/A LENZ Therapeutics, Inc. Filed by: FMR LLC

Thu, 05 Feb 2026 13:28:00 -0500

si-local-file:///var/storage/secattach/20260205/25953620.html

LENZ Therapeutics Inc (LENZ) PT Lowered to $35 at BofA Securities

Wed, 04 Feb 2026 05:36:11 -0500

BofA Securities analyst Jason Gerberry lowered the price target on LENZ Therapeutics Inc (NASDAQ: LENZ) to $35.00 (from $52.00) while maintaining a Buy rating.

The analyst comments "We update our LENZ model incorporating preliminary 4Q net product revenue of $1.6m (vs cons $1m) & early script trends for Vizz (presbyopia). The net impact of a slower Yr1+ ramp leads us to lower our peak sales outlook to $770m (from $840m, or -10%) and cut our '27-'32E Vizz forecast -25% on average, reducing our PO to $35/shr (from $52). On the one hand, early volume uptake looks encouraging with >20K prescriptions in

LENZ Therapeutics Inc (LENZ) PT Lowered to $35 at BofA Securities

Wed, 04 Feb 2026 05:36:11 -0500

BofA Securities analyst Jason Gerberry lowered the price target on LENZ Therapeutics Inc (NASDAQ: LENZ) to $35.00 (from $52.00) while maintaining a Buy rating.

Form SCHEDULE 13G/A LENZ Therapeutics, Inc. Filed by: BlackRock, Inc.

Wed, 21 Jan 2026 12:32:00 -0500

si-local-file:///var/storage/secattach/20260121/25873771.html

Form SCHEDULE 13G/A LENZ Therapeutics, Inc. Filed by: BlackRock, Inc.

Wed, 21 Jan 2026 12:32:00 -0500

si-local-file:///var/storage/secattach/20260121/25873771.html

LENZ Therapeutics and Sarah Jessica Parker announce the launch of "Make it VIZZable", the VIZZ consumer campaign

Wed, 14 Jan 2026 08:30:00 -0500

Struggling to see up close? VIZZ is a revolutionary, once-daily eye drop and alternative to reading glasses to restore near vision for up to 10 hours

The "Make it VIZZable" campaign features SJP enjoying the everyday convenience of clear near vision provided by using the VIZZ eye drops.

VIZZ is available nationwide by prescription through eye doctors; visit VIZZ.com to learn more and to find a local provider offering a free sample

SAN DIEGO, Jan. 14, 2026 /PRNewswire/ -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or "LENZ" or

LENZ Therapeutics and Sarah Jessica Parker announce the launch of "Make it VIZZable", the VIZZ consumer campaign

Wed, 14 Jan 2026 08:30:00 -0500

Struggling to see up close? VIZZ is a revolutionary, once-daily eye drop and alternative to reading glasses to restore near vision for up to 10 hours

The "Make it VIZZable" campaign features SJP enjoying the everyday convenience of clear near vision provided by using the VIZZ eye drops.

VIZZ is available nationwide by prescription through eye doctors; visit VIZZ.com to learn more and to find a local provider offering a free sample

SAN DIEGO, Jan. 14, 2026 /PRNewswire/ -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or "LENZ" or

LENZ Therapeutics and Sarah Jessica Parker announce the launch of "Make it VIZZable", the VIZZ consumer campaign

Wed, 14 Jan 2026 08:30:00 -0500

Struggling to see up close? VIZZ is a revolutionary, once-daily eye drop and alternative to reading glasses to restore near vision for up to 10 hours

The "Make it VIZZable" campaign features SJP enjoying the everyday convenience of clear near vision provided by using the VIZZ eye drops.

VIZZ is available nationwide by prescription through eye doctors; visit VIZZ.com to learn more and to find a local provider offering a free sample

SAN DIEGO, Jan. 14, 2026 /PRNewswire/ -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or "LENZ" or

LENZ Therapeutics and Sarah Jessica Parker announce the launch of "Make it VIZZable", the VIZZ consumer campaign

Wed, 14 Jan 2026 08:30:00 -0500

Struggling to see up close? VIZZ is a revolutionary, once-daily eye drop and alternative to reading glasses to restore near vision for up to 10 hours

The "Make it VIZZable" campaign features SJP enjoying the everyday convenience of clear near vision provided by using the VIZZ eye drops.

VIZZ is available nationwide by prescription through eye doctors; visit VIZZ.com to learn more and to find a local provider offering a free sample

SAN DIEGO, Jan. 14, 2026 /PRNewswire/ -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or "LENZ" or

Form 8-K LENZ Therapeutics, Inc. For: Jan 07

Wed, 07 Jan 2026 17:10:00 -0500

si-local-file:///var/storage/secattach/20260107/25821126.html

Form 8-K LENZ Therapeutics, Inc. For: Jan 07

Wed, 07 Jan 2026 17:10:00 -0500

si-local-file:///var/storage/secattach/20260107/25821126.html

Form 8-K LENZ Therapeutics, Inc. For: Jan 07

Wed, 07 Jan 2026 17:10:00 -0500

si-local-file:///var/storage/secattach/20260107/25821127.html

Form 8-K LENZ Therapeutics, Inc. For: Jan 07

Wed, 07 Jan 2026 17:10:00 -0500

si-local-file:///var/storage/secattach/20260107/25821127.html

LENZ Therapeutics Reports Fourth Quarter 2025 Preliminary Unaudited Financial Results and Recent Corporate Updates

Wed, 07 Jan 2026 17:08:00 -0500

Launched VIZZ™ (aceclidine ophthalmic solution) 1.44% in October 2025 for the treatment of presbyopia, with broad product availability in mid-November 2025

Achieved approximately $1.6 million in net product revenue with over 20,000 prescriptions filled in Q4 2025

Over 6,500 unique ECPs prescribed VIZZ; more than 55% have prescribed multiple times in Q4 2025

SAN DIEGO, Jan. 07, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ™ (aceclidine ophthalmic solution) 1.44%, the first and only aceclidine-based eye drop for

LENZ Therapeutics Reports Fourth Quarter 2025 Preliminary Unaudited Financial Results and Recent Corporate Updates

Wed, 07 Jan 2026 17:08:00 -0500

Launched VIZZ™ (aceclidine ophthalmic solution) 1.44% in October 2025 for the treatment of presbyopia, with broad product availability in mid-November 2025

Achieved approximately $1.6 million in net product revenue with over 20,000 prescriptions filled in Q4 2025

Over 6,500 unique ECPs prescribed VIZZ; more than 55% have prescribed multiple times in Q4 2025

LENZ Therapeutics Reports Fourth Quarter 2025 Preliminary Unaudited Financial Results and Recent Corporate Updates

Wed, 07 Jan 2026 17:08:00 -0500

Launched VIZZ™ (aceclidine ophthalmic solution) 1.44% in October 2025 for the treatment of presbyopia, with broad product availability in mid-November 2025

Achieved approximately $1.6 million in net product revenue with over 20,000 prescriptions filled in Q4 2025

Over 6,500 unique ECPs prescribed VIZZ; more than 55% have prescribed multiple times in Q4 2025

LENZ Therapeutics Reports Fourth Quarter 2025 Preliminary Unaudited Financial Results and Recent Corporate Updates

Wed, 07 Jan 2026 17:08:00 -0500

Launched VIZZ™ (aceclidine ophthalmic solution) 1.44% in October 2025 for the treatment of presbyopia, with broad product availability in mid-November 2025

Achieved approximately $1.6 million in net product revenue with over 20,000 prescriptions filled in Q4 2025

Over 6,500 unique ECPs prescribed VIZZ; more than 55% have prescribed multiple times in Q4 2025

Form 4 LENZ Therapeutics, Inc. For: Jan 02 Filed by: Schimmelpennink Evert B.